Solution Group to supply Cansino vaccine in Malaysia


SOLUTION Group Berhad’s wholly-owned subsidiary, Solution Biologics Sdn Bhd (SolBio) has signed a finished product and a bulk product agreement with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine for use against Covid-19.

In a statement, the group said the finished product agreement allows SolBio to purchase and CanSino to supply the finished product vaccine for emergency use in Malaysia. 

It added that the bulk agreement will see CanSino supply the active pharmaceutical ingredients for the fill-and-finish to SolBio, in which both agreements come with a period of ten years with immediate effect.

Solution Group deputy group MD Datuk Dr Mohd Nazlee Kamal said the first shipment of the finished doses will be delivered by August, and the subsequent batches are also on schedule.

“The CanSino vaccine being a single-dose vaccine makes it more efficient to administer, especially in rural and difficult-to-reach areas, which makes for huge savings in terms of logistics and other resources needed to be deployed for the nationwide vaccination programme,” he added.

Through the signing of both agreements, SolBio can fulfill its obligation to supply 3.5 million doses of Covid-19 vaccine to the Ministry of Health (MoH) and accept additional orders from MoH, state governments, the private sector, and other Asean countries. 

Additionally, SolBio would have the capacity to supply booster shots, should it be required for those who have been fully inoculated with other Covid-19 vaccines.

Mohd Nazlee said with the supply agreement, the group is confident to fulfil more than the government’s current requirement.

“We believe the supply of the vaccine known as Convidecia will help to boost the vaccination rate in Malaysia sharply to meet the government’s accelerated target of immunising the country’s entire population against Covid-19 by Oct this year,” he noted.

He also added that the bulk product agreement will enable SolBio to do the fill-and-finish in Malaysia and supply in Malaysia, the Philippines, Vietnam, Thailand, Myanmar, Cambodia, Laos, Brunei, and Singapore. 

CanSino has also authorised SolBio to develop the business in these countries for the vaccine through working with respective local partners, authorities, and regulatory bodies.

Mohd Nazlee said the group’s primary focus is to fulfil the supply of 3.5 million doses of the vaccine to MoH which it had signed in early April this year and expect to complete by Oct 2021.